MedTrace Logo

Oral Bioavailability of Two Solid Formulations of GLPG0259.

NCT01322451 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2011-03-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate the relative bioavailability of two solid oral formulations of GLPG0259 administered after a meal.

Conditions

  • Healthy

Interventions

DRUG

GLPG0259 fumarate

single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate

DRUG

GLPG0259 free base

single oral dose, GLPG0259, 50 mg solid formulation

Sponsors & Collaborators

  • Galapagos NV

    lead INDUSTRY

Principal Investigators

  • Johan Beetens, PharmD, PhD · Galapagos NV

  • Lien Gheyle, MD · SGS Stuivenberg

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01322451 on ClinicalTrials.gov